<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567149</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0</org_study_id>
    <nct_id>NCT02567149</nct_id>
  </id_info>
  <brief_title>Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.</brief_title>
  <official_title>Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine whether intralesional cidofovir is effective at&#xD;
      bringing about the total or near-total resolution of warts that have already proven&#xD;
      recalcitrant to standard therapy.&#xD;
&#xD;
      The secondary objective is to determine the tolerability of this new mode of administration&#xD;
      of cidofovir in the pediatric population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes pediatric patients with history of either primary or iatrogenic&#xD;
      immune-suppression who are seeking treatment of warts that have already proven recalcitrant&#xD;
      to standard therapy. The first cohort will include 4 patients ages 12 to 17. After all tests&#xD;
      indicate treatment safety, the second cohort will be recruited and will include patients ages&#xD;
      8 to 17.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding&#xD;
  </why_stopped>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical resolution of treated warts as evaluated by the investigators</measure>
    <time_frame>6 months</time_frame>
    <description>Total or near-total clinical resolution of treated warts as evaluated by the investigators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of wart-associated symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>2. Patient-perceived improvement of wart-associated symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient/parent reported tolerability of the treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Warts</condition>
  <arm_group>
    <arm_group_label>Cidofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cidofovir clinical resolution of treated warts as evaluated by the investigators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir</intervention_name>
    <description>Cidofovir</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. The first cohort will include a total of 4 patients ages 12 to 17. After all tests&#xD;
             indicate treatment safety, the second cohort will be recruited and will include&#xD;
             patients ages 8 to 17.Patient is in immune-suppressed status by one of the following:&#xD;
&#xD;
               1. Primary immunodeficiency, which may include but is not limited to the following:&#xD;
&#xD;
                    1. Chronic Granulomatous Disease (CGD)&#xD;
&#xD;
                    2. Common Variable Immunodeficiency (CVID)&#xD;
&#xD;
                    3. DiGeorge Syndrome (DGS)&#xD;
&#xD;
                    4. Selective IgA Deficiency&#xD;
&#xD;
                    5. Severe Combined Immunodeficiency (SCID)&#xD;
&#xD;
                    6. X-Linked Agammaglobulinemia (XLA)&#xD;
&#xD;
               2. Pharmacologic immune-suppressed status from medications including but not limited&#xD;
                  to:&#xD;
&#xD;
                    1. prednisone&#xD;
&#xD;
                    2. cyclosporine&#xD;
&#xD;
                    3. azathioprine&#xD;
&#xD;
                    4. tacrolimus/ FK506&#xD;
&#xD;
                    5. mycophenolate mofetil&#xD;
&#xD;
                    6. sirolimus&#xD;
&#xD;
                  2. Patient has history of clinically-significant warts that are either refractory&#xD;
                  to standard therapy or for which standard therapy is contra-indicated or&#xD;
                  unreasonable 3. Patient has a total wart burden of at least 1cm 4. Patients must&#xD;
                  have tried and failed at least 2 other conventional treatments for cutaneous&#xD;
                  warts, including but not limited to:&#xD;
&#xD;
                    -  cryotherapy&#xD;
&#xD;
                    -  topical salicylic acid&#xD;
&#xD;
                    -  imiquimod&#xD;
&#xD;
                    -  topical 5FU&#xD;
&#xD;
                    -  pulsed dye laser therapy&#xD;
&#xD;
                    -  sinecatechins&#xD;
&#xD;
                    -  tretinoin or other topical retinoid&#xD;
&#xD;
                    -  intralesional candida injection&#xD;
&#xD;
                    -  bleomycin&#xD;
&#xD;
                    -  electrocautery&#xD;
&#xD;
                    -  topical cidofovir cream or gel&#xD;
&#xD;
                  There will be a one month washout period for all treatment modalities, with the&#xD;
                  exception of intralesional candida, which will be 3 months.&#xD;
&#xD;
                  5. Patient desires ongoing treatment of their warts 6. Patient and/or their&#xD;
                  parent/guardian consents to participating in this study&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
               1. Treatment area is either ulcerated, secondarily infected, or significantly&#xD;
                  inflamed&#xD;
&#xD;
               2. Treatment area is on face or groin area&#xD;
&#xD;
               3. Patient is pregnant, attempting to become pregnant, or lactating&#xD;
&#xD;
               4. Patient reports active kidney disease, or chart review reveals recent serum&#xD;
                  creatinine â‰¥1.5mg/dL or a history of renal disease/insufficiency or history of&#xD;
                  diabetes&#xD;
&#xD;
               5. Patient is currently receiving a nephrotoxic medication&#xD;
&#xD;
               6. Patient has history of hypersensitivity to cidofovir&#xD;
&#xD;
               7. Patient is severely ill and/or hospitalized&#xD;
&#xD;
               8. Patient is receiving chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Polcari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cidofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

